Unmet clinical needs
Dry AMD and other retinal disorders affect more than 200 million people worldwide, with limited curative options.
Topical retinal therapeutics
From Injections to Non-Invasive: Redefining Retinal Disease Treatment.
Eyescure is developing safer, less invasive and more accessible therapies for retinal disease through a proprietary topical ocular delivery platform.
Delivery platform
Breaking the Corneal Barrier for Precise Drug Delivery.
A sustained-release, bioadhesive gel matrix is designed to extend residence time and support retinal target exposure.
Eye health ecosystem
Beyond Treatment: Building a Full-Cycle Eye Health Ecosystem.
Alongside drug candidates, Eyescure offers wellness products that support modern eye care routines.
First-in-class ambition
Collaborating with Top Scientific Institutions, Driven by Integrated Innovation.
The lead program focuses on dry AMD and retinitis pigmentosa, with Anti-VEGF topical candidates in expansion.
Why Eyescure
A full-cycle retinal and eye health strategy
Treatment paradigm shift
The topical platform aims to move ophthalmic care away from repeated injections toward non-invasive use.
Integrated product ecosystem
Therapeutic candidates, adjuvant devices and wellness products cover treatment, rehabilitation and prevention.
Latest news
Lead asset IND-enabling work in preparation
Q3 2024: Compound CNTF Gel concluded full preclinical studies, with IND-enabling activities now being prepared.
Review preclinical direction2020Founded
3Pipeline assets
200M+Potential patients
Featured video
Opening film and product vision
A cinematic introduction to Eyescure's technology direction and eye health portfolio.
Our Company
Founded to solve ocular barrier penetration and improve patient experience.
Our Science
A proprietary gel platform designed for posterior-segment delivery.
Products & Solutions
Therapeutic candidates plus adjuvant care and wellness products.
Responsibility
Patient-centered development, scientific integrity and social engagement.
Partners
Collaboration with ophthalmology hospitals, research institutions and clinical partners.
About Eyescure
Building a needle-free future for retinal therapy
Eyescure was founded in 2020 to address the pain, procedural risk and lifestyle burden of conventional intraocular injection therapy.
Mission
Safer, non-invasive ophthalmic solutions
We deliver ophthalmic therapies and eye health solutions globally through breakthrough delivery technology and integrated innovation.
Vision
A world-leading topical retinal therapeutics company
Our goal is to become a global innovator in topical retinal therapy and comprehensive eye health management.
Therapeutic focus
Posterior-segment retinal disease
Programs are organized around retinal indications where invasive treatment burden remains high.
Translational model
Preclinical-to-clinical readiness
Development priorities emphasize formulation, pharmacology, safety and regulatory preparation.
Partnership posture
Global collaboration ready
Eyescure is positioned for scientific, clinical, investor and channel partnerships.
Our story
Solving the ocular barrier challenge
Conventional injections preserve vision but can create pain, procedural risk and repeated hospital visits. Eyescure set out to create topical formulations that deliver active agents to retinal lesions without needles.
The company combines biopharmaceutical delivery technology with evidence-based traditional Chinese wellness principles to build a holistic eye health ecosystem.
Leadership
Scientific and translational expertise
CS
Chief Scientific Advisor
Led by a nationally renowned ophthalmology expert from the China Academy of Chinese Medical Sciences, with more than 30 years of posterior-segment disease experience.
RD
Core R&D Team
PhD-level experts in pharmaceutics, molecular biology and medical device engineering with extensive preclinical and translational research experience.
Milestones
Development path
- Company founded
- Core formulation finalized; proof-of-concept completed
- Preclinical program completed for Compound CNTF Gel
- Pipeline expansion into Anti-VEGF topical candidates and wellness products
- Preparing IND submission for flagship therapeutic asset
- Planned IND clearance and Phase I launch
- Planned Phase I advancement and Phase II preparation
Products & Solutions
Therapeutic pipeline and eye health portfolio
Eyescure separates investigational retinal therapeutics from wellness products, with each portfolio positioned for the appropriate clinical, regulatory and commercial pathway.
Core therapeutic pipeline
A topical portfolio for retinal disease
Asset
Indications
Status
Clinical value
Compound CNTF Gel
dry AMD, retinitis pigmentosa
Preclinical completed; IND-enabling preparation
Potential first topical neuroprotective candidate for dry AMD.
Anti-VEGF Gel
wet AMD
Discovery and IP filing
Designed as a non-invasive alternative to repeated intravitreal Anti-VEGF injections.
Compound CNTF + VEGF Formulation
mixed and severe AMD
Discovery and formulation
Dual-pathway mechanism for complex retinal pathology.
Lead programCompound CNTF Gel
Primary indicationsDry AMD / Retinitis Pigmentosa
Development pathIND-enabling preparation
Adjuvant therapy
Ivicure® Meridian Eye Massager
A smart periocular care device combining TCM meridian acupoint theory with modern microcurrent technology. It supports local circulation and helps relieve eye fatigue.
- Microcurrent neuromuscular stimulation
- Multiple intelligent therapy modes
- Ergonomic portable design
Product use
Demonstration video
Wellness portfolio
Eyescure® Guben Qingmu Granules
Formulated with food-medicine homologous botanicals including wolfberry fruit, chrysanthemum flower and cassia seed for daily nutritional eye support.
Daily care
OPSCURE® Guben Qingmu Herbal Eye Care Patch
Disposable herbal eye patches infused with botanical actives. Use alone for 15-20 minutes or combine with the massager for daily eye care.
Adjuvant Therapy & Wellness Portfolio
Explore daily eye care products
Explore and purchase our non-prescription eye care devices and wellness products designed to support your daily eye health.
Science & Innovation
Engineering topical delivery to the posterior retina
Eyescure is focused on solving the layered ocular barrier challenge that limits traditional eye drops.
Delivery platform
Bioadhesive sustained-release gel matrix
The patented platform is designed to extend ocular surface residence time and enable active molecules to cross the cornea, aqueous humor, lens and vitreous body, reaching therapeutic levels at retinal target sites.
1Topical gel
2Barrier crossing
3Retinal target
Mechanisms of action
Two complementary scientific paths
CNTF neuroprotection
CNTF can upregulate protective pathways, modulate overactive complement responses and protect photoreceptors from apoptotic loss.
Anti-VEGF conversion
Anti-VEGF remains the standard for pathological neovascularization; Eyescure is working to convert this modality into patient-friendly topical formulations.
Preclinical proof of concept
Signals observed in dry AMD animal models
Competitive landscape
A low-competition topical opportunity
More than 70 dry AMD investigational assets are in global development, but most rely on intravitreal injection or oral administration. Topical posterior-segment therapeutics represent a differentiated entry point.
Responsibility
Responsible innovation governed by science and ethics
Eyescure aligns development decisions with patient benefit, scientific integrity, regulatory readiness and responsible commercialization.
Patient benefit
Programs are prioritized around meaningful reductions in treatment burden, procedural risk and access barriers.
Scientific integrity
Research claims are grounded in reproducible preclinical data, transparent limitations and appropriate regulatory context.
Quality culture
Teams operate with documentation discipline, cross-functional review and respect for clinical and manufacturing standards.
Responsible operations
Future scale-up will consider resource use, supplier practices and environmentally responsible operating principles.
Access and education
Eyescure plans eye health education and access initiatives for communities with unmet ophthalmic needs.
Governance
Built for regulated healthcare markets
- Clear separation between investigational therapeutics and wellness products.
- Medical claims framed according to development stage and approval status.
- Partnership discussions supported by scientific and regulatory documentation.
Partners
Clinical and scientific partnerships for eye health
Eyescure is building collaborations with ophthalmology hospitals, research institutions and channel partners to advance retinal therapeutics and eye health services.
Ophthalmology hospitals
Reserved for future hospital cooperation, clinical collaboration, patient education and real-world eye health programs.
Research institutions
Scientific collaboration around topical retinal delivery, ophthalmic pharmacology and translational research.
Commercial partners
Channel development and service partnerships for compliant access to eye health products and support programs.
Partner showcase
Reserved for hospital and institutional partner display
- Partner logos, hospital names and institutional profiles.
- Cooperation projects, clinical service pilots and education programs.
- Milestones and collaboration outcomes as partnerships progress.
Online Shop
Official Eyescure Online Shop
Welcome to the official Eyescure Online Shop. Here, you can conveniently and securely purchase our carefully developed adjuvant therapy and daily eye wellness products for professional eye care.
Device
Ivicure® Meridian Eye Massager
An intelligent microcurrent eye care device designed to relieve visual fatigue and support periocular circulation.
¥1,299.00
Wellness
Eyescure® Guben Qingmu Granules
Food-medicine homologous ingredients for internal nourishment, liver-clearing support and eye comfort.
¥168.00
Daily care
OPSCURE® Guben Qingmu Herbal Eye Care Patch
Herbal botanical ingredients for external eye-area care, designed for gentle daily support.
¥89.00
Shop-specific disclaimer
Daily eye care and fatigue relief
The products sold in this shop are wellness devices and health products intended for daily eye care and fatigue relief. They are not drugs or therapeutic medical devices and are not intended to diagnose, treat, cure, or prevent any disease (including retinal diseases such as AMD). All prescription-stage investigational drugs are not available for sale in this shop.
Contact Us
Connect with Eyescure
For partnering, investor relations, scientific exchange, channel development or general enquiries, please contact the appropriate Eyescure team.
Licensing, co-development, distribution and strategic collaboration.
Financing discussions, corporate updates and investor materials.
Product information, media requests and general enquiries.
Eyescure (Suzhou) BE Co., Ltd.
- Address
- Room 305-4, Building 23, Suhua Science Park, 208 Tongyuan Road, Suzhou Industrial Park, Jiangsu Province, P.R.China
- Business Cooperation
- partnership@eyescure.com
- Investor Relations
- ir@eyescure.com
- General Inquiries
- info@eyescure.com
Site Map
Explore the Eyescure website
Use this map to quickly reach the main sections, product information, science platform, partner area and contact channels.